[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer].

Hepatic infusion of docetaxel using PEIT was performed for a patient with stage IV breast cancer. Docetaxel was effective to a solitary liver metastatic lesion. A 64-year-old woman was admitted to our hospital because of a left breast mass that was bleeding. She was diagnosed with stage IV breast cancer. Surgery was performed on February 16th. The pathological diagnosis was invasive ductal carcinoma, and hormone receptors were negative. Two weeks after operation, monthly docetaxel injections were given together with doxifluidine 400 mg/day p.o., cyclophosphamide 50 mg/day p.o., and fadrozole hydrochloride hydrate 2 mg/day p.o. After two courses, hepatic infusion of docetaxel was performed using PEIT after informed consent. The patient's high serum CEA and CA15-3 level returned to the normal range. A metastatic lesion on CT changed to a cystic pattern. These results suggest that PEIT is worth trying in patients with solitary liver metastasis from breast cancer.

Peroral jejunoscopy for treating stenosis of hepaticojejunostomy after pancreatoduodenectomy.

A 72-year-old woman suffered from relapsing cholangitis after pylorus-preserving pancreatoduodenectomy for chronic pancreatitis. The common hepatic duct had been anastomosed to the jejunum 8 cm distal to the duodenojejunostomy. Peroral jejunoscopy showed a severe stenosis of the hepaticojejunostomy, which was endoscopically enlarged by means of electroincision and balloon dilation, subsequently. No procedure-related complications occurred. The patient has been asymptomatic for 34 months. Most of the strictures of bilioenterostomy are reportedly treated by surgical revision, the percutaneous transhepatic approach, or the percutaneous transjejunal approach. Endoscopic treatment may be attempted in cases in which the postoperative anatomy potentially allows endoscopic access, because of its minimal invasiveness and effectiveness.

[Mutagenicity of benzene metabolites by fluctuation test].

Mutagenicity of five benzene metabolites was examined by a fluctuation test modified by Gatehouse. The test was performed by using Salmonella typhimurium TA100 with or without a metabolic activation system. Catechol showed mutagenic activity with and without a metabolic activation system in the fluctuation test. Hydroxyhydroquinone, phenol, hydroquinone and p-benzoquinone were positive only with a metabolic activation system in this test. The Ames' plate method and preincubation method are widely used as a screening test for the mutagenic compounds. However, the fluctuation test is very useful in detecting mutagenic activity of chemicals which are negative in the Ames test though being a mutagen or carcinogen.

[Comparative study on the mutagenic activity of rat liver and bladder S9 by fluctuation test].

Mutagenicity of seven aromatic amines, two heterocyclic amines, two azo compounds and one polycyclic aromatic hydrocarbon was examined with a fluctuation test modified by Gatehouse. The test was performed by using Salmonella typhimurium TA98 in the presence of liver and bladder S9 from PCB pretreated rats. Seven out of 12 compounds showed mutagenic activities with liver S9 and seven with bladder S9. Benzidine, 3-methylcholanthrene and 2-acetylaminofluorene showed a negative response with bladder S9 but a positive response with liver S9. The mutagenicity of the seven compounds observed with bladder S9 had a lower sensitivity than with liver S9. 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole and 3-amino-1-methyl-5H-pyrido[4,3-b]indole showed mutagenic activity at lower concentrations than the other compounds which showed mutagenic activity either with bladder S9 or liver S9. Mutagenicity of 3-methylcholanthrene was observed at high concentration only in the presence of liver S9. The findings from the present study suggested that aromatic amines, heterocyclic amines and polycyclic aromatic hydrocarbons were more likely to be activated to strong mutagens with liver S9 than with bladder S9.